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The Journal of Immunology
Vitronectin Inhibits Efferocytosis through Interactions with
Apoptotic Cells as well as with Macrophages
Hong-Beom Bae,*,† Jean-Marc Tadie,*,‡ Shaoning Jiang,* Dae Won Park,*,x
Celeste P. Bell,* Lawrence C. Thompson,{ Cynthia B. Peterson,{ Victor J. Thannickal,*
Edward Abraham,‖ and Jaroslaw W. Zmijewski*
Effective removal of apoptotic cells, particularly apoptotic neutrophils, is essential for the successful resolution of acute inflam-
matory conditions. In these experiments, we found that whereas interaction between vitronectin and integrins diminished the
ability of macrophages to ingest apoptotic cells, interaction between vitronectin with urokinase-type plasminogen activator
receptor (uPAR) on the surface of apoptotic cells also had equally important inhibitory effects on efferocytosis. Preincubation
of vitronectin with plasminogen activator inhibitor-1 eliminated its ability to inhibit phagocytosis of apoptotic cells. Similarly,
incubation of apoptotic cells with soluble uPAR or Abs to uPAR significantly diminished efferocytosis. In the setting of LPS-
induced ALI, enhanced efferocytosis and decreased numbers of neutrophils were found in bronchoalveolar lavage obtained from
vitronectin-deficient (vtn2/2) mice compared with wild type (vtn+/+) mice. Furthermore, there was increased clearance of apoptotic
vtn2/2 as compared with vtn+/+ neutrophils after introduction into the lungs of vtn2/2 mice. Incubation of apoptotic vtn2/2
neutrophils with purified vitronectin before intratracheal instillation decreased efferocytosis in vivo. These findings demonstrate
that the inhibitory effects of vitronectin on efferocytosis involve interactions with both the engulfing phagocyte and the apoptotic
target cell. The Journal of Immunology, 2013, 190: 2273–2281.
T
he removal of apoptotic cells, a process known as effero-
cytosis, plays a crucial role in the maintenance of tissue
homeostasis and resolution of inflammatory and immune
responses (1–3). Failure to effectively remove apoptotic cells, and
particularly apoptotic neutrophils that accumulate in inflammatory
foci, results in necrosis and cytolysis of dying cells with the con-
comitant release of tissue damaging intracellular contents. Recent
studies have shown that the ability of host to effectively remove
apoptotic cells has important effects on outcome in experimental
models for sepsis, hemorrhage, burns, or endotoxin-induced acute
lung injury (ALI), conditions that are clinically relevant particu-
larly in the setting of critical illness (4–6).
Recognition of apoptotic cells by phagocytes is mediated by “eat-
me” signaling components that appear on the surface of the apo-
ptotic cell (1, 2, 7–11). Phosphatidylserine, calreticulin, CD14, and
oxidized low-density lipoprotein-like moiety are well-characterized
apoptotic cell surface markers that are involved in the engulfment of
apoptotic cells by phagocytes (12–15). Recent studies suggest that
factors released by apoptotic cells, including lysophosphatidylcho-
line or endothelial monocyte-activating polypeptide II, as well as
the nucleotide extracellular gradient, participate in “find-me” sig-
naling, resulting in the accumulation of phagocytes around apo-
ptotic cells (16–18). Some receptors are also capable of preventing
the recognition of dying cells. For example, the appearance of
complexes of CD31–CD31 or CD47 signal regulatory protein a on
the surface of apoptotic cells allows them to escape phagocytosis
(19, 20). In addition to ligands appearing on the cell surface, soluble
factors, including Gas6 and protein S, that bridge phosphatidylser-
ine and phagocytic receptors of the TAM family (Tyro3, Axl, and
Mer) enhance the uptake and ingestion of apoptotic cells by mac-
rophages and other phagocytic cells (21). Finally, cytoskeletal re-
arrangement that allows for engulfment of the targeted cell and
formation of phagosomes is required for effective clearance of ap-
optotic cells by phagocytes (22–24).
Vitronectin is a multifunctional glycoprotein found in large
quantities in serum, the extracellular matrix, and platelets. Vitro-
nectin consists of three distinct domains: a somatomedin B domain
(SMB) that binds to the urokinase-type plasminogen activator
receptor (uPAR); a short Arg-Gly-Asp (RGD) motif that interacts
with integrins; and a hemopexin domain that forms complexes with
heparin/complement (25–30). The ability of vitronectin to interact
with these regulatory components affects cell adhesion, coagula-
tion, fibrinolysis, complement activation, and apoptosis (31, 32).
Recent studies suggest that interactions between vitronectin and
integrin avb3, plasminogen activator inhibitor-1 (PAI-1), or uPAR
can also modulate the clearance of apoptotic cells (33–35). The
ability of vitronectin to affect biological processes associated with
inflammation is likely to have pathophysiologic significance be-
cause tissue levels of vitronectin in the lungs and other anatomic
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sites are markedly increased in settings such as ALI, burns, and
sepsis that are associated with neutrophil activation and tissue
injury (36, 37).
In the present studies, we investigated the ability of vitronectin
to modulate clearance of apoptotic cells under in vitro and in vivo
conditions. Our results indicate that vitronectin can diminish
efferocytosis by independently affecting the participation of both
macrophages and apoptotic cells.
Materials and Methods
Mice
Vitronectin-deficient mice (B6.129S2[D2]-Vtntm1Dgi/J), as well as control
mice (C57BL/6J), were purchased from The Jackson Laboratory (Bar
Harbor, ME). Vitronectin knockout male mice were crossed to B6D2F1/J
female mice and then backcrossed to C57BL/6J for 12 generations before
being interbred. Male mice, 8–12 wk of age, were used for experiments.
All experiments were conducted in accordance with Institutional Review
Board–approved protocols (University of Alabama at Birmingham Insti-
tutional Animal Care and Use Committee).
Materials
Purified mouse vitronectin was purchased from Abcam (Cambridge, MA).
Vitronectin lacking the SMB domain, d SMB mutant (DSMB), or isolated
SMB domain were expressed in Drosophila S2 cells using methods re-
ported by Schar et al. (38), and proteins purified as described by Thomp-
son et al. (39). Cyclo(Arg-Gly-Asp-D-Phe-Val) RGDfv and cyclo(Arg-
Ala-Asp-D-Phe-Val) RADfv were purchased from Enzo Life Science
(Plymouth Meeting, PA), whereas RGD-FITC was from AnaSpec (Fremont,
CA). Recombinant mouse PAI-1 was a gift from Dr. Victoria Ploplis
(Notre Dame, IN). Soluble uPAR (suPAR) were obtained from R&D
Systems (Minneapolis, MN). Neutralizing Ab to integrin avb3 was from
Millipore (Billerica, MA), and specific isotype control IgG was purchased
from BD Biosciences (San Diego, CA). Mouse-specific anti-integrin avb5
blocking Ab and isotype control IgG were a gift from Dr. Dean Sheppard
(University of California, San Francisco, CA). Anti-uPAR blocking Ab
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). For
immunocytochemistry, anti-vitronectin and anti-uPAR Abs were from
R&D Systems, whereas Alexa Fluor 488 and Alexa Fluor 555 secondary
Abs were purchased from Invitrogen (Carlsbad, CA). Mouse-specific anti-
avb3 and -avb5 Abs for immunocytochemistry were purchased from
Novus Biologicals (Littleton, CO), whereas anti-6His Ab was from Santa
Cruz Biotechnology. Propidium iodide and Abs to Annexin V were ob-
tained from EMD Chemicals (Gibbstown, NJ). PKH26 was from Sigma-
Aldrich (St. Louis, MO), whereas FITC-conjugated anti-CD11b and
allophycocyanin-conjugated anti-CD 90.2 Abs were from BD Biosciences
(San Diego, CA). Custom Ab mixtures and negative selection columns for
neutrophil isolation were purchased from Stem Cell Technologies (Van-
couver, BC, Canada). ELISA kits for measuring vitronectin were obtained
from Molecular Innovations (Novi, MI).
Neutrophil and thymocyte isolation and culture
Bone marrow neutrophils were purified using a negative selection column
(40, 41). In brief, bone marrow cell suspensions were isolated from the
femur and tibia of mice by flushing with RPMI 1640 medium with 5%
FBS. The cell suspension was passed through a glass wool column and
collected by washing with PBS containing 5% FBS. Negative selection to
purify neutrophils was performed by incubation of the cell suspension with
biotinylated primary Abs specific for the cell-surface markers F4/80, CD4,
CD45R, CD5, and TER119 (Stem Cell Technologies; http://www.stemcell.
com/en/Products/Cell-type/Granulocytes-subsets.aspx) for 15 min at 4˚C
followed by subsequent incubation with anti-biotin tetrameric Abs (100 ml;
Stem Cell Technologies) for 15 min. The complex of anti-tetrameric Abs
and cells was then incubated with colloidal magnetic dextran iron particles
(60 ml; Stem Cell Technologies) for an additional 15 min at 4˚C. The
T cells, B cells, RBCs, monocytes, and macrophages were captured in a
column surrounded by a magnet, allowing the neutrophils to pass through.
Neutrophil purity, as determined by Wright-Giemsa–stained cytospin
preparations, was consistently .98%. Thymocytes were isolated as pre-
viously described (42).
Purification and culture of peritoneal macrophages
Peritoneal macrophages were elicited in 8 to 10-wk-old mice using Brewer
thioglycollate. Cells were collected 5 d after i.p. injection of Brewer thi-
oglycollate and were plated on coverslips (Fisherbrand 12-545-82 12CIR-
1D; Fisher Scientific, Middletown, VA) in 24-well plates (2.5 3 105 cells/
well) in serum-free RPMI 1640 medium. After 1 h, the plates were washed
with culture medium to remove nonadherent cells. Macrophages were
cultured in RPMI 1640 medium and used for phagocytosis assays on the
day of isolation.
Induction of apoptosis in neutrophils and thymocytes
Apoptosis in neutrophils and thymocytes was induced as previously de-
scribed. In brief, apoptosis in vtn+/+ or vtn2/2 neutrophils was induced by
incubation of the cells for 45 min at 43˚C, followed by culture for an
additional 2.5 h at 37˚C. Murine thymocytes (vtn+/+ or vtn2/2, 6 3 106
cells/ml) in RPMI 1640 medium were incubated with dexamethasone (1
mM) for 16 h. Cells were then washed three times with RPMI 1640 me-
dium to remove dexamethasone. Annexin/PI staining and flow cytometry
showed that $90% of the thymocytes and .70% of the neutrophils were
apoptotic.
In vitro efferocytosis assay
In vitro efferocytosis assays were performed as previously described (43). In
brief, 2.5 3 106 apoptotic neutrophils or 106 apoptotic thymocytes sus-
pended in RPMI 1640 medium were cocultured with 2.5 3 105 macro-
phages on glass coverslips. Cells were incubated in media containing 5%
mouse serum obtained from vtn+/+ or vtn2/2 mice for 2 or 1.5 h, as in-
dicated in the figure legends. Next, coverslips were washed three times
with ice-cold PBS and cells stained with HEMA 3 (Fisher Scientific).
Phagocytosis was evaluated by a blinded observer by counting for five to
six randomly selected fields per slide. The phagocytosis index was cal-
culated as the percentage of macrophages containing at least one engulfed
neutrophil or thymocyte.
In vivo efferocytosis assay
In vivo efferocytosis was determined as previously described (6, 34). In
brief, the effect of vitronectin on phagocytosis was determined using in-
tratracheal (i.t.) instillation of apoptotic neutrophils into vtn+/+ or vtn2/2
mice anesthetized with isoflurane. Mice were injected i.t. with 5 3106
vtn+/+ or vtn2/2 viable or apoptotic neutrophils, or vtn2/2 apoptotic neu-
trophils that were preincubated with purified vitronectin (100 nM) for 1 h.
Two hours later, the mice were sacrificed and bronchoalveolar lavage (BAL)
performed using 1 ml sterile PBS containing 5 mM EDTA. Cells were then
collected on cytospin slides, fixed, stained with HEMA 3, and phagocytosis
index was determined by a blinded observer.
In selected experiments, apoptosis was induced in thymocytes that were
labeled with PKH-26 red fluorescent dye. Mice were anesthetized with
isoflurane, and 1 3 107 apoptotic thymocytes/PKH-26 in 50 or 100 ml PBS
were injected i.t. or i.p., respectively, as described in the figure legends. Two
hours later, mice were sacrificed and BAL or peritoneal lavage performed
using 1 or 5 ml sterile PBS containing EDTA (5 mM), respectively. Isolated
cells were washed with culture media and then incubated in PBS containing
1% albumin, FITC-conjugated anti-CD11b, and allophycocyanin-conjugated
anti-CD90.2 (thymocyte marker) Abs followed by flow cytometry analysis.
The phagocytic index was calculated as the ratio of FITC+PKH26+allo-
phycocyanin2 cells to all cells gated. Engulfed thymocytes are not accessible
to the allophycocyanin-conjugated anti-CD90.2 Ab. Therefore, FITC+
PKH26+allophycocyanin2 cells are identified as macrophages that have
engulfed PKH-labeled thymocytes, whereas the FITC+PKH26+allophyco-
cyanin+ cells are macrophages that contain adherent thymocytes (e.g., not
engulfed).
Imaging thymocytes, neutrophils, and macrophages
Viable or apoptotic thymocytes were incubated with 4% paraformaldehyde
in PBS for 20 min at room temperature. Cells were washed with PBS,
preincubated with 1%BSA in PBS for 45 min, and then incubated with anti-
uPAR Abs (1:50 dilution) overnight at 4˚C followed by fluorescent anti-
rabbit Ab (Alexa 488, 1:1000 dilution) for 90 min at room temperature.
Cells were washed with PBS and mounted with an emulsion oil solution
containing DAPI to visualize nuclei. Microscopy was performed using a
confocal laser scanning microscope (model LSM 710 confocal micro-
scope; Carl Zeiss MicroImaging) provided by the High Resolution Imag-
ing Facility at the University of Alabama at Birmingham. Viable and
apoptotic neutrophils were incubated with 4% paraformaldehyde, washed
with PBS, blocked with 3% BSA, and then cultured with Abs to uPAR
(1:20) and vitronectin (1:25) for 2 h followed by incubation with fluo-
rescent anti-rat Alexa-488 and anti-rabbit Alexa-555 Abs at 1:1000 dilution
for an additional 90 min at room temperature to determine colocalization
between uPAR and vitronectin. In selected experiment, cells treated with
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RGD-FITC or vitronectin-DSMB-6His for 60 min were stained with anti-
avb3, anti-avb5, or anti-6His Ab (90 min at room temperature) and specific
fluorescent secondary Abs (for additional 60 min).
ELISA vitronectin
Amount of vitronectin in culture medium or BALs was determined using
mouse-specific vitronectin kit (Molecular Innovations, Novi, MI), and
accordingly with instruction and vitronectin protein standard provided by
manufacturer.
Model for LPS-induced ALI
ALI was induced by i.t. administration of 1 mg/kg LPS in 50 ml PBS as
previously described (40, 41, 44, 45). In brief, mice were anesthetized with
isoflurane, the tongue was gently extended, and LPS in PBS or PBS alone
(control) was deposited into the pharynx. Mice were sacrificed 48 h after
LPS administration, and BAL was obtained by lavaging the lungs three
times with 1 ml PBS.
Statistical analysis
Statistical significance was determined by the Wilcoxon rank sum test
(independent two-group Mann–Whitney U test), as well as Student t test
for comparisons between two groups. Multigroup comparisons were per-
formed using one-way ANOVAwith the Turkey’s post hoc test. A p value
,0.05 was considered significant. Analyses were performed on SPSS
version 16.0 for Windows.
Results
Vitronectin diminishes engulfment of apoptotic cells by
macrophages
The ability of vitronectin to affect efferocytosis was determined
using peritoneal macrophages and apoptotic thymocytes or neu-
trophils. Cells were obtained from wild type mice (vtn+/+) or mice
deficient in vitronectin (vtn2/2). Consistent with previous studies
(33), complete deficiency of vitronectin in the cultures (e.g., vtn2/2
cells and medium-containing serum from vtn2/2 mice) was as-
sociated with markedly increased phagocytosis of apoptotic thy-
mocytes as compared with that found when vtn+/+ macrophages
and apoptotic cells were included in the cultures (Fig. 1A, 1B).
The effects of vitronectin deficiency were reversible on coincu-
bation of vtn2/2 cells with serum obtained from wild type mice
(vtn+/+). Of note, the inhibitory effects of vitronectin were depen-
dent on cell viability, in particular, exposure to vitronectin dimin-
ished the engulfment of apoptotic cells (Fig. 1B), but had no effect
on the low rate of uptake of viable cells by macrophages. As was
found with apoptotic thymocytes, vitronectin deficiency also in-
creased uptake of apoptotic neutrophils by peritoneal macrophages
(Fig. 1C).
Vitronectin diminishes efferocytosis through interactions with
macrophages, as well as with apoptotic cells
To determine whether the inhibition of efferocytosis by vitronectin
was mediated by binding of vitronectin to receptors on the surface
of macrophages or apoptotic cells, or perhaps by affecting both
cell types, vtn2/2 macrophages cultured in vitronectin-deficient
medium were dose-dependently treated with purified vitronectin
or vtn+/+ serum obtained from wild type mice, then washed and
cocultured with vitronectin-deficient apoptotic thymocytes in
vitronectin-deficient medium. As shown in Fig. 2A and Supple-
mental Fig. 1A, inclusion of either purified vitronectin or serum-
containing vitronectin dose- dependently decreased the ability of
macrophages to ingest apoptotic thymocytes. Decreases in effero-
cytosis were also found when apoptotic vtn2/2 thymocytes were
preincubated with purified vitronectin or vitronectin-containing
medium followed by coculture with vtn2/2 macrophages (Fig.
2B or Supplemental Fig. 1B). The lowest levels of phagocytosis
were found when both vtn2/2 macrophages and apoptotic cells
were treated with vitronectin (Fig. 2C). As expected, large
amounts of vitronectin were detected in vtn+/+ serum, whereas no
vitronectin was found in vtn2/2 serum (Supplemental Fig. 1G).
Western blot analysis, confocal microscopy, and ELISA con-
firmed the ability of purified vitronectin or vitronectin in serum
to bind to viable and apoptotic vtn2/2 cells (Supplemental Fig. 1E,
1F, 1H).
FIGURE 1. Vitronectin deficiency increases phago-
cytosis of apoptotic cells. Macrophages were cocul-
tured with apoptotic or viable thymocytes (vtn+/+ or
vtn2/2) or neutrophils (vtn+/+ or vtn2/2) for 90 or 120
min, respectively. Cells were incubated in serum ob-
tained from wild type (vtn+/+) or vitronectin-deficient
(vtn2/2) mice as indicated. Representative images
(original magnification 340) (A) and phagocytic in-
dices (B, C) show that vitronectin deficiency (vtn2/2)
increased phagocytosis of apoptotic thymocytes or
apoptotic neutrophils. Cells were stained with HEMA
3. Means6 SD (n = 3). Arrows in (A) indicate ingested
apoptotic thymocytes. ***p , 0.001 compared vtn+/+
apoptotic cells cultured in vtn2/2 serum, **p , 0.01
compared vtn2/2 apoptotic cells cultured in vtn2/2
serum with vtn2/2 apoptotic cells cultured in vtn+/+
serum, #p , 0.05 compared with viable cells.
The Journal of Immunology 2275












Vitronectin domains differentially affect the interactions
between macrophages and apoptotic thymocytes during
efferocytosis
Preincubation of apoptotic thymocytes with full-length vitronectin
or with the vitronectin SMB domain alone produced similar in-
hibition of efferocytosis, but exposure of apoptotic thymocytes to
vitronectin lacking the SMB domain (vitronectin-DSMB) had no
effect of efferocytosis (Fig. 3A). In contrast with apoptotic thy-
mocytes, exposure of vtn2/2 macrophages to full-length vitro-
nectin or vitronectin-DSMB, but not to the SMB domain alone,
resulted in inhibition of efferocytosis (Fig. 3E). Of note, confocal
microscopy confirmed that vitronectin-DSMB was colocalized
with avb3 and avb5 integrins on the cell surface of peritoneal
macrophages (Supplemental Fig. 2A, 2B). These results suggest
that whereas the SMB domain of vitronectin is involved in
diminishing efferocytosis through interaction with receptors on
apoptotic cells, other domains of vitronectin are responsible for its
inhibitory effect on ingestion of apoptotic cells by macrophages.
Vitronectin is known to interact with the avb3 integrin and
appears able to inhibit the stimulatory effects of avb3 on effero-
cytosis (33, 46, 47). Consistent with such previously reported
findings, incubation of macrophages with specific Abs that block
the avb3 integrin resulted in decreased uptake of apoptotic thy-
mocytes (Fig. 3F). However, a similar approach to selectively
block the avb3 integrin on apoptotic thymocytes had no effect on
efferocytosis (Fig. 3B). Similar results were obtained with specific
FIGURE 2. Vitronectin inhibits efferocytosis through interactions with both apoptotic cells and macrophages. (A) Vtn2/2 macrophages or (B) vtn2/2
apoptotic thymocytes were pretreated with purified vitronectin (0, 30, 100, or 300 nM) in medium without serum for 1 h. The cells were then washed and
cocultured in medium supplemented with 5% serum (vtn2/2) for 90 min. The percentage of ingested thymocytes is shown. Means6 SD (n = 3); *p, 0.05,
**p , 0.01 compared with untreated cells. (C) Vtn2/2 macrophages or vtn2/2 apoptotic thymocytes were separately pretreated with purified vitronectin (0
or 200 nM) for 60 min, then washed and cocultured in medium containing vitronectin-deficient serum (5%) for an additional 90 min. Means 6 SD (n = 3);
**p , 0.01 or ***p , 0.001 compared with untreated cells, whereas ##p , 0.01 compared with macrophages cocultured with apoptotic thymocytes, both
pretreated with purified vitronectin.
FIGURE 3. Effects of vitronectin, vitronectin
SMB domain, vitronectin deficient in SMB domain
(DSMB), RGD peptide, or Abs to avb3 on effero-
cytosis. (A–D) Apoptotic vtn2/2 thymocytes or (E–
H) vtn2/2 macrophages were pretreated with vitro-
nectin (vtn, 0 or 200 nM), SMB domain (0 or 200
nM), DSMB (0 or 200 nM), anti-avb3 or anti-avb5
Ab (1 mg/ml), isotype-specific IgG (1 mg/ml),
RGDfv (1 mM), or RADfv (1 mM) for 1 h and then
washed. The percentage of engulfed thymocytes was
determined after coculture of macrophages with
apoptotic thymocytes for 90 min. In selected ex-
periments, cells were treated with anti-avb3 or avb5
Ab or RGDfv for 60 min, washed, and then cultured
with purified vitronectin for an additional 60 min.
Means 6 SD (n = 3) are shown. (A) ***p , 0.001
compared with control (untreated) or cells pretreated
with DSMB only; (B) ***p , 0.001 compared with
control, anti-avb3, or IgG pretreated; (C) **p ,
0.01, ***p , 0.001 compared with IgG or anti-avb5;
(D) ***p , 0.001 compared with control, RGD, or
RAD treated; (E) ***p , 0.001 compared with
control or SMB treated; (F) **p , 0.01 compared
with control and IgG; (G) *p , 0.05 (p = 0.036) and
**p , 0.01 compared with IgG; and (H) ***p ,
0.001 compared with control and macrophages pre-
treated with RAD.
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Abs that block the avb5 integrin (Fig. 3C, 3G). These results
demonstrate that in addition to its interactions with avb3, vitro-
nectin can potentially modulate efferocytosis through binding
between its RGD domain and the avb5 integrin (33, 48, 49).
Previous studies (33), as well as results shown in Fig. 3H, dem-
onstrate that preincubation of macrophages with the RGD peptide
RGDfv or with full-length vitronectin effectively diminished the
ability of macrophages to engulf apoptotic cells. In contrast, ex-
posure of apoptotic thymocytes to RGDfv did not affect effero-
cytosis and also did not affect vitronectin-dependent inhibition of
efferocytosis (Fig. 3D, 3H). These results suggest that the inhib-
itory effects of vitronectin on efferocytosis are mediated by binding
to integrins on the surface of macrophages, but were integrin in-
dependent in the case of apoptotic cells. Notably, confocal micro-
scopy revealed colocalization between FITC-RGD peptide and avb3
or avb5 integrins in both macrophages and apoptotic neutrophils
(Supplemental Fig. 2C, 3A).
Interactions between vitronectin and uPAR on the surface of
apoptotic cells inhibit efferocytosis
As shown in Fig. 4A and 4B, full-length vitronectin or purified
vitronectin SMB domain diminished efferocytosis of apoptotic
vtn2/2 thymocytes. Because the vitronectin SMB domain is known
to bind to the uPAR (50, 51), we hypothesized that such interactions
might be a relevant mechanism for the ability of vitronectin to affect
the uptake of apoptotic cells by macrophages. Indeed, exposure of
vtn2/2 apoptotic thymocytes to uPAR blocking Abs or deficiency of
uPAR (uPAR2/2 thymocytes) resulted in inhibition of efferocytosis
(Fig. 4A, 4D). Although a previous study (52) and the current ex-
periments found decreased uPAR staining on the surface of apo-
ptotic cells, uPAR was still readily detected on apoptotic thymo-
cytes (Fig. 4E, Supplemental Fig. 3B). As shown in Fig. 4E,
confocal microscopy revealed that uPAR also interacts with
vitronectin.
Interactions between vitronectin with PAI-1 and uPAR are
mutually exclusive, although PAI-1 was demonstrated to have
higher affinity for vitronectin than does uPAR (28, 53). Because
SMB diminished efferocytosis, we anticipated that formation of
PAI-1–SMB complexes will diminish binding between SMB and
uPAR on the surface of apoptotic cells and preserve efficient
clearance of such cells. As shown in Fig. 4B, preincubation of
vtn2/2 apoptotic thymocytes with preformed complexes of PAI-1–
SMB diminished the ability of the vitronectin SMB domain to
inhibit efferocytosis. Of note, there was no evidence that the
effects of PAI-1 were due to potential contamination with LPS
(Supplemental Fig. 1C).
FIGURE 4. uPAR on the surface of apoptotic cells contributes to the ability of vitronectin to inhibit efferocytosis. (A) Apoptotic thymocytes (vtn2/) were
pretreated with blocking Ab to uPAR (0 or 1 mg/ml) or isotype-specific IgG (0 or 1 mg/ml) for 30 min. Cells were washed and then treated with purified
vitronectin (0 or 200 nM) for an additional 60 min. Phagocytic indices were determined after thymocytes were washed to remove unbound vitronectin
followed by coculture for 90 min with macrophages in medium containing vitronectin-deficient serum (5%). Means 6 SD (n = 3); ***p , 0.001 compared
with control (untreated) or macrophages pretreated with IgG alone. (B) Apoptotic thymocytes were preincubated with PAI-1 (0 or 100 nM), SMB (0 or 100
nM), or preformed PAI-1/SMB complexes for 60 min. PAI-1/SMB complexes were obtained after incubation of PAI-1 with SMB for 60 min at room
temperature. Phagocytic indices are shown. Means 6 SD (n = 3); **p , 0.01, comparing thymocytes incubated with SMB to control or treated with PAI-1
or PAI-1/SMB. (C) Phagocytic indices were obtained after apoptotic thymocytes were pretreated with vitronectin (0 or 200 nM), suPAR (0 or 200 nM),
vitronectin/suPAR complexes, or vitronectin incubated with BSA. Means 6 SD (n = 3); **p , 0.01 compared with control or thymocytes treated with
suPAR alone or vitronectin/suPAR. (D) Phagocytic indices obtained after apoptotic wild type (uPAR+/+) or uPAR-deficient (uPAR2/2) thymocytes were
cocultured with wild type macrophages. Means 6 SD (n = 3); **p , 0.01. (E) Representative confocal images (original magnification 360) show the
amount and colocalization (yellow) of vitronectin and uPAR on the surface of viable or apoptotic neutrophils (arrows). Fluorescent immunostaining shows
uPAR (red), vitronectin (green) and nuclei (blue).
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Previous studies have shown that suPAR can bind to av, b1, b2,
or b3 integrins (25, 35, 54), as well as to SMB domain of vitro-
nectin (30). Therefore, we examined whether interactions between
suPAR and vitronectin could affect efferocytosis. Inclusion of
suPAR preincubated with vitronectin into cultures of vtn2/2 ap-
optotic thymocytes increased the phagocytic index as compared
with treatment with vitronectin alone (Fig. 4C). However, unlike
the situation with apoptotic cells, macrophages preincubated with
suPAR still demonstrated diminished engulfment of apoptotic thy-
mocytes after exposure to vitronectin (Supplemental Fig. 1D).
Vitronectin decreases efferocytosis in vivo
Although our experiments demonstrated that vitronectin can inhibit
efferocytosis in vitro, we wished to confirm that such effects of
vitronectin were also present under in vivo conditions. To examine
this issue, we induced ALI by pulmonary exposure to LPS, a sit-
uation known to result in the appearance of significant amounts of
vitronectin in interstitial lung tissue, as well as in the alveolar space
(Fig. 5E) (36, 37). As shown in Fig. 5, engulfment of apoptotic
neutrophils was significantly increased in the lungs of LPS-treated
vtn2/2 as compared with vtn+/+ mice. Decreased numbers of neu-
trophils were recovered from BAL fluid of vtn2/2 as compared with
vtn+/+ mice.
Although these results suggest that deficiency of vitronectin can
enhance the clearance of apoptotic neutrophils, another possibility
is that there were increased numbers of neutrophils undergoing
efferocytosis as a result of greater levels of apoptosis. To address
this issue, we subjected vtn+/+ or vtn2/2 mice to i.t. administration
of purified apoptotic vtn+/+ or vtn2/2 neutrophils and then de-
termined phagocytic indices. As shown in Fig. 6A, clearance of
apoptotic neutrophils was significantly increased in vtn2/2 mice
injected with vtn2/2 neutrophils as compared with vtn+/+ mice
that were injected with vtn+/+ neutrophils. Of note, significantly
less vitronectin was found in the lungs of control mice as com-
pared with mice exposed to LPS (Fig. 5E). i.t. administration of
purified vitronectin into the lungs of control (vtn+/+) mice also
decreased efferocytosis after instillation of vtn2/2 apoptotic neu-
trophils (Fig. 6B).
Apoptotic vtn2/2 neutrophils or thymocytes were incubated with
or without vitronectin, then washed and injected i.t. into vtn2/2
mice to determine whether vitronectin can affect efferocytosis by
specifically binding to apoptotic cells. As shown in Fig. 6C, there
was decreased phagocytosis by alveolar macrophages of apoptotic
cells that had been treated with purified vitronectin. Similar results
were obtained from experiments in which fluorescently labeled
apoptotic vtn2/2 thymocytes were preincubated with or without
purified vitronectin and then injected into the lungs of vtn2/2 mice
(Fig. 6D). Confirmatory results were obtained using fluorescently
labeled vtn2/2 apoptotic thymocytes preincubated with or without
vitronectin that were then injected into the i.p. cavity of vtn2/2mice
(Fig. 6E). These data indicate that vitronectin plays a regulatory role
in efferocytosis in vivo through interactions with receptors on the
surface of apoptotic cells (Fig. 7).
Discussion
In these experiments, we found that vitronectin effectively inhibits
uptake of apoptotic cells by macrophages in vitro and in the lungs
of mice with LPS-induced ALI. Our results showed that inter-
actions between vitronectin and apoptotic cells, as well as between
vitronectin and macrophages, prevent efferocytosis. However, the
mechanisms for such inhibition of efferocytosis by vitronectin were
dependent on interaction with differing receptors on macrophages
and apoptotic cells. Although we found that vitronectin decreased
phagocytosis by binding to the avb3 and avb5 integrin on the
surface of macrophages, this did not appear to be the case for
apoptotic cells. Using cells isolated from vitronectin-deficient
mice, Abs to selective cell-surface receptors, and specific vitro-
nectin domains, we found that the inhibitory effects of vitronectin
on the uptake of apoptotic cells by macrophages were mediated by
interactions with the uPAR on the apoptotic cell.
Previous studies demonstrated that vitronectin receptors, in-
cluding avb3 and the combination of PAI-1 and uPAR, can modulate
the phagocytosis of apoptotic cells (33–35, 55). However, the
direct role of vitronectin on efferocytosis has not been fully ex-
plored. Proteins able to bridge receptors on apoptotic cells and
phagocytes, including vitronectin, milk fat globule EGF factor 8
(MFG-E8), or thrombospondin-1 (TSP-1), have been reported to
participate in efferocytosis through binding to avb3 on macro-
phages (33, 46, 47, 56). Vitronectin can diminish interactions
between avb3 and bridging molecules, such as MFG-E8 or TSP-1,
thereby preventing recognition of phosphatidylserine on apoptotic
cells (46, 47). In the present studies, incubation of macrophages
with Abs to avb3 or RGDfv decreased their ability to ingest ap-
optotic cells. Of note, interactions between avb3 and vitronectin or
the RGD peptide on macrophages, but not on apoptotic cells, have
previously been shown to inhibit association of macrophages with
apoptotic cells (33, 46, 57).
Previous studies have shown that the SMB domain of vitronectin
is required for binding to uPAR (25, 28, 30). In the present
experiments, culture of apoptotic cells with purified vitronectin
SMB domain, but not with vitronectin lacking the SMB domain,
diminished efferocytosis. These results indicate that uPAR on the
surface of apoptotic cells is likely to be a target for the SMB
domain of vitronectin. Indeed, similar to the inhibitory effects on
efferocytosis found after incubation of the SMB domain with
apoptotic cells, inactivation of uPAR on apoptotic cells by incu-
bation with blocking Abs also diminished phagocytosis. These
data suggest that the ability of vitronectin to bind uPAR on apo-
ptotic cells inhibits an important “eat-me” signal that normally
FIGURE 5. Vitronectin deficiency enhances clearance of apoptotic
neutrophils in the lungs of mice with LPS-induced ALI. The percentage of
macrophages with ingested neutrophils was determined in BAL fluid ob-
tained from mice that received LPS (i.t.) 48 h previously. (A) Represen-
tative images (original magnification 3100) of macrophages engulfing
apoptotic neutrophils. (B) Phagocytic indices. (C and D) Total white cells
and neutrophil numbers in BAL; (E) amount of vitronectin detected in
BAL obtained from control mice and mice subjected to i.t. LPS admin-
istration. Means 6 SD; n = 3, *p , 0.05 compared with vtn or **p , 0.01
compared control with LPS-treated mice.
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would enhance the uptake of apoptotic cells by macrophages.
Notably, avb3 on apoptotic cells appeared to be dispensable in
regulating efferocytosis, as evidenced by the lack of effect when
apoptotic cells were preincubated with Abs that block avb3 or
with RGDfv, unlike the inhibition of efferocytosis found when mac-
rophages were exposed to such agents.
uPAR affects many cellular functions, including the adhesion
of cells to vitronectin and other matrix proteins (25, 58, 59). suPAR
is released by cleavage of the uPAR GPI anchor in the plasma
membrane (25, 50). As is the case for uPAR, suPAR is known to
associate with av, b1, b2, and b3 integrins (35, 54, 60, 61). In ad-
dition, association between suPAR and b3 integrins can be ef-
FIGURE 6. Effects of vitronectin on clearance of
apoptotic cells in vivo. (A) Phagocytic index was de-
termined by measuring ingestion of apoptotic neu-
trophils by alveolar macrophages using BAL from mice
(vtn+/+ or vtn2/2) obtained 2 h after i.t. administration of
apoptotic neutrophils (vtn+/+ or vtn2/2). Means 6 SD
with three mice per group, *p , 0.05. (B) Wild type
(vtn+/+) mice received purified vitronectin i.t. (0 or 1 mg)
30 min before instillation of vtn+/+ apoptotic neutrophil.
BAL was obtained 2 h later. The percentages of alveolar
macrophages with ingested neutrophils are shown.
Means 6 SD from three mice per group. *p , 0.05. (C)
Apoptotic neutrophils (vtn2/2) were incubated with pu-
rified vitronectin (0 or 200 nM) for 1 h, washed, and then
administered i.t. to vitronectin-deficient (vtn2/2) mice.
Phagocytic indices were determined in BAL obtained
2 h after neutrophil administration. Means 6 SD (four
mice/group) are shown. *p , 0.05 compared with mice
that received neutrophils that were incubated without
vitronectin. (D) Mice were treated as described in (C)
using PKH26-labeled apoptotic thymocytes (vtn2/2) that
were preincubated with or without vitronectin. Phago-
cytic indices were determined using flow cytometry.
Means 6 SD (four mice/group) are shown. *p , 0.05
compared with the mice given untreated thymocytes. (E)
Mice were subjected to i.p. injection of PKH26-labeled
apoptotic thymocytes (vtn2/2) treated with or without
vitronectin. Peritoneal cells were isolated 2 h later and
phagocytic indices determined using flow cytometry.
Means 6 SEM using three mice per group.
FIGURE 7. The SMB domain and RGD motif of vitronectin inhibit efferocytosis through selective binding to integrins on macrophages and by binding
to uPAR on apoptotic cells.
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fectively blocked by RGDfv (54). These previous findings raise
the possibility that suPAR can interfere with binding on the sur-
face of macrophages between integrins, such as avb3, and extra-
cellular ligands including MFG-E8 or TSP-1. Notably, our
experiments found that exposure of apoptotic cells to suPAR had
minimal or no effect on efferocytosis (Supplemental Fig. 1). How-
ever, because suPAR can bind to vitronectin, such interactions
between vitronectin and suPAR are likely to prevent binding of
vitronectin to uPAR on the apoptotic cell, thereby blocking the
ability of vitronectin to inhibit efferocytosis, a finding confirmed
in our experiments.
The specific mechanisms by which interactions between vitro-
nectin, uPAR, and integrins affect efferocytosis have not been
completely elucidated. The SMB domain of vitronectin has been
shown to bind to the D1 domain and D1-D2 linker region of uPAR,
and such interactions may affect the association of uPAR with
integrins through the uPAR D2 and/or D3 domains (30, 62–64).
Our findings reveal a novel mechanism by which vitronectin
can inhibit efferocytosis and potentially affect the resolution of
neutrophil-associated inflammatory processes, such as those that
occur in ALI. Severe sepsis, hemorrhage, burns, and ventilator-
induced lung injury are associated with increased tissue levels of
vitronectin, including in the pulmonary interstitium and alveolar
space (36, 37). Notably, previous studies demonstrated that the
severity of LPS-induced ALI is diminished in vitronectin-deficient
(vtn2/2) mice (37). Our present results show that deficiency of
vitronectin also is associated with diminished clearance of apo-
ptotic neutrophils in the lungs of mice with LPS-induced lung
injury. In addition, preincubation of apoptotic cells with vitro-
nectin diminished their uptake by alveolar macrophages after in-
stillation into the lungs. These findings suggest that therapeutic ap-
proaches that inhibit binding between vitronectin with uPAR on
apoptotic neutrophils should increase efferocytosis and, therefore,
may diminish the severity of ALI and other inflammatory pro-
cesses in which neutrophils play a major role.
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